Management of chronic hepatitis C virus infection in HIV-infected patients

Clinical Infectious Diseases

Volumn 47, Issue 1, 2008, Pages 94-101

  Pol, Stanislas ^a,b   Soriano, Vincent ^c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Hôpital Cochin ^*  (France)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; NUCLEOSIDE DERIVATIVE; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; PROTEINASE INHIBITOR; RIBAVIRIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; PEGINTERFERON ALFA-2B;

BONE MARROW SUPPRESSION; CD4 LYMPHOCYTE COUNT; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; DISEASE CONTROL; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INFECTION RISK; LIVER DISEASE; LIVER TOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIREMIA; VIRUS LOAD; RANDOMIZED CONTROLLED TRIAL;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIBAVIRIN;

EID: 46249116795     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/588669     Document Type: Review

References (51)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345:41-52.
2. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006; 130:231-64.
3. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39:1147-71.
4. Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. Clin Infect Dis 2005; 40(Suppl 3):S131-235.
5. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-60.
6. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32:492-7.
7. Monga HK, Rodriguez-Barradas MC, Breaux K, et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 33:240-7.
8. Soriano V, Sulkowski M, Bergin C, et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002; 16:813-28.
9. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451-9.
10. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292:2839-48.
11. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-50.
12. Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004; 18:F27-36.
13. Crespo M, Sauleda S, Esteban JI, et al. Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients. J Viral Hepat 2007; 14:228-38.
14. Bani-Sadr F, Goderel I, Morand P, et al. High hepatitis C virus viral load in HIV/hepatitis C virus-co-infected patients: a different influence of protease inhibitor and non-protease inhibitor-based HAART? AIDS 2007; 21:1645-8.
15. Bani-Sadr F, Denoeud L, Morand P, et al. Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role? J Acquir Immune Defic Syndr 2007; 45:123-5.
16. Vispo E, Barreiro P, Maida I, et al. Abacavir-containing HAART reduces the chances for sustained virological response to pegylated-interferon plus ribavirin in HIV-infected patients with chronic hepatitis C. In: Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago, IL). 2007.
17. Pineda JA, Mira JA, Gil IL, et al. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients. J Antimicrob Chemother 2007; 60:1347-54.
18. Alberti A, Clumeck N, Collins S, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42:615-24.
19. Laguno M, Larrousse M, Murillas J, et al. Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin. J Acquir Immune Defic Syndr 2007; 44:174-8.
20. Crespo M, Esteban JI, Ribera E, et al. Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients. AIDS 2007; 21:477-81.
21. Payan C, Pivert A, Morand P, et al. Rapid and early virological response to chronic hepatitis C treatment with IFN α2b or PEG-IFN or α2b plus ribavirin in HIV/HCV co-infected patients. Gut 2007; 56:1111-6.
22. Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001; 357:280-1.
23. Alvarez D, Dieterich DT, Brau N, Moorehead L, Ball L, Sulkowski MS. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepat 2006; 13:683-9.
24. Bani-Sadr F, Goderel I, Penalba C, et al. Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin. J Viral Hepat 2007; 14:639-44.
25. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123:1061-9.
26. Sola R, Galeras JA, Montoliu S, et al. Poor response to hepatitis C virus (HCV) therapy in HIV- and HCV-coinfected patients is not due to lower adherence to treatment. AIDS Res Hum Retroviruses 2006; 22:393-400.
27. Gilleece YC, Browne RE, Asboe D, et al. Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. J Acquir Immune Defic Syndr 2005; 40:41-6.
28. Dominguez S, Ghosn J, Valantin M-A, et al. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS 2006; 20:1157-61.
29. Servoss JC, Sherman KE, Robbins G, et al. Hepatotoxicity in the U.S. adult AIDS clinical trial group. Gastroenterology 2001; 120(Suppl 1):A-54.
30. Servoss JC, Kitch DW, Andersen JW, Reisler RB, Chung RT, Robbins GK. Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989-1999). J Acquir Immune Defic Syndr 2006; 43:320-3.
31. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283:74-80.
32. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35:182-9.
33. Mehta SH, Thomas DL, Torbenson M, et al. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology 2005; 41:123-31.
34. Eramova I, Matic S, Munz M. Management of hepatitis C and HIV coinfection: clinical protocol for the WHO European region, World Health Organization Europe Web site, 2007. Available at: http://www.euro.who. int/Document/E90840.pdf. Accessed 24 April 2007.
35. Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected person. Ann Intern Med 2003; 138:197-207.
36. National Institutes of Health consensus statement on management of hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19:1-46.
37. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21:1073-89.
38. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122:1303-13.
39. Soriano V, Maida I, Nunez M, et al. Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies. Antiviral Therapy 2004; 9:987-92.
40. Nunez M, Miralles C, Berdun MA, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses 2007; 23:972-82.
41. O'Shea D, Kevans D, Tuite H, et al. Role of very early viral response in prediction of sustained virological response to peg-IFN + ribavirin in HIV/HCV-co-infected and HCV-mono-infected individuals [abstract 894]. In: Program and abstracts of the 14th Congress on Retroviruses and Opportunistic Infections (Los Angeles, CA). 2007.
42. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357:124-34.
43. Sanchez-Tapias JM, Diago M, Escartin P, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131:451-60.
44. Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130:1086-97.
45. Pearlman B, Ehleben C, Saifee S. Improved virologic response rates with treatment extension to 72 weeks of peginterferon alfa-2b plus weight-based ribavirin in a difficult-to-treat population of genotype 1-infected slow responders. Hepatology 2007; 44(Suppl 1):318A.
46. Mangia A, Minerva N, Bacca D, et al. In pts who clear HCV RNA at week 12, SVR is higher after 72 than after 48 weeks tx: results of a randomized controlled trial (RCT). In: Program and abstracts of the 42nd Annual Meeting of the European Association for the Study of the Liver (Barcelona, Spain). 2007.
47. Nunez M, Garcia-Samaniego J, Portu J, et al. The PRESCO trial: impact of higher ribavirin doses and longer duration of therapy with peginterferon alfa-2a plus ribavirin in HIV-infected patients with chronic hepatitis C. In: Program and abstracts of the 57th Annual Meeting of the American Association for the Study of Liver Diseases (Boston). 2006.
48. Myers RP, Benhamou Y, Bochet M, Thibault V, Mehri D, Poynard T. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy. AIDS 2004; 18:75-9.
49. Labarga P, Vispo E, Barreiro P, et al. Re-treatment with pegylated interferon lus weight-adjusted ribavirin in HIV+ patients with chronic hepatitis C: the PILOT-NR study. Hepatology 2007; 46(Suppl 1):393A.
50. Pol S, BourliereM. Optimizing treatment outcomes in chronic hepatitis C: management of non-response. Antiviral Therapy 2006; 11:955-70.
51. Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged antiviral therapy with peginterferon to prevent complications of advanced liver disease associated with hepatitis C: results of the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology 2007; 46(Suppl 1):290A.